Sign Up to like & get
recommendations!
0
Published in 2019 at "Hematology"
DOI: 10.1080/10245332.2018.1509461
Abstract: ABSTRACT Objectives: Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with rituximab (R-CHOP) is currently the first-line therapy for diffuse large B-cell lymphoma (DLBCL). However, management of elderly patients is challenging and often requires dose…
read more here.
Keywords:
cyclophosphamide doxorubicin;
reduced dose;
vincristine prednisolone;
doxorubicin vincristine ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.ade1846
Abstract: Cyclophosphamide and doxorubicin lead to premature ovarian insufficiency as an off-target effect. However, their oocyte death pathway has been debated. Here, we clarified the precise mechanism of ovarian depletion induced by cyclophosphamide and doxorubicin. Dormant…
read more here.
Keywords:
cyclophosphamide doxorubicin;
dna damage;
tap63 determines;
oocyte death ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2018.7774
Abstract: Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical…
read more here.
Keywords:
cyclophosphamide doxorubicin;
rituximab plus;
vincristine prednisolone;
diffuse large ... See more keywords